Ataxia-telangiectasia, often shortened to A-T, is a rare inherited condition affecting several body systems. Its name describes problems coordinating movement and small, widened blood vessels visible in the eyes or skin. But the condition also involves immunity, lung health and cancer risk. Understanding A-T requires both a clinical assessment and careful interpretation of genetic findings. MedlinePlus Genetics describes these features.
What ATM does in cells
The ATM gene contains instructions for a protein that helps cells respond to damaged DNA. Rather than repairing every break itself, the protein helps recognize damage and activates other proteins involved in repair. It also helps regulate cell growth and division. These functions matter in the nervous system, immune system and other tissues. MedlinePlus explains ATM function.
Disease-causing ATM variants can reduce or remove this protein’s function. Cells then respond abnormally to DNA damage. Loss of cells in the cerebellum, a brain region involved in coordination, contributes to movement difficulties. Disrupted control of DNA damage also helps explain the increased cancer risk. This biological explanation does not predict exactly which complications an individual will develop. ATM and disease.
Recognizing a range of presentations
In classic A-T, coordination problems usually become apparent in early childhood. Speech and eye movements can also be affected. Some people have weakened immune responses and repeated respiratory infections. Cancer risk is increased, particularly for leukemia and lymphoma. These features do not all have to appear together. Clinical features of A-T.
A milder form, called variant A-T, may have a different movement pattern and generally normal immune function. The visible blood vessels can appear years after movement symptoms. Their absence early on therefore does not exclude A-T. GeneReviews describes the clinical spectrum.
One affected gene copy and two answer different questions
A-T is an autosomal recessive condition: disease-causing variants affect both copies of ATM. Someone with one inherited pathogenic ATM variant does not have A-T on that basis. However, carrying one such variant can increase cancer risk, particularly breast cancer risk in women. The phrase “an ATM finding” therefore needs clarification before its meaning is clear. ATM inheritance and carrier implications.
Understanding family probabilities
When both parents carry a disease-causing variant for the same recessive condition, each pregnancy has three possible genetic outcomes:
- A 25% chance of a child inheriting two disease-causing copies.
- A 50% chance of a child inheriting one disease-causing copy.
- A 25% chance of a child inheriting neither parental disease-causing copy.
These probabilities apply separately to each pregnancy. A previous child’s result does not change the next pregnancy’s probabilities. They describe inheritance, not how severe a condition will be. Applying them to a family requires knowing the relevant parental findings; a gene name alone is insufficient. Genetics professionals can help explain the results and reproductive choices. MedlinePlus explains recurrence probabilities.
What testing can establish—and leave unresolved
Diagnosis combines suggestive clinical findings with pathogenic or likely pathogenic variants affecting both ATM copies. Two uncertain variants do not establish the diagnosis. Testing methods also differ: sequence analysis may need additional analysis for missing or duplicated gene segments. A result must be interpreted alongside what the laboratory actually examined. GeneReviews diagnostic guidance.
Established care and research have different roles
There is currently no cure. Supportive care addresses function, communication, nutrition, immunity and respiratory complications. Unusual sensitivity to ionizing radiation also affects clinical planning. MedlinePlus summarizes management and radiation sensitivity.
GeneReviews lists experimental approaches under therapies being investigated. That designation does not establish routine benefit. Research findings need evaluation for meaningful improvement, harms and durability before they can support wider clinical use. Meanwhile, coordinated specialist care and ongoing assessment remain central to managing established disease. GeneReviews distinguishes supportive care from investigational therapies.